Table 2:
Results from the GEE Model, Prevalence Cohort 2007–2011
| Percentage change* | Coefficient | 95% CI | ||
|---|---|---|---|---|
| Age group (reference group: age 65–69) | ||||
| 70–74 | 0.9% | 0.0086 | −0.039 | 0.056 |
| 75–79 | 5.8% | 0.0560 | 0.003 | 0.110 |
| >=80 | 0.8% | 0.0081 | −0.047 | 0.063 |
| Race group (reference group: non-Hispanic white) | ||||
| Non-Hispanic black | 39.8% | 0.3349 | 0.263 | 0.406 |
| Hispanic/non-Hispanic other races | −2.6% | −0.0261 | −0.099 | 0.046 |
| Sex (reference group: female) | ||||
| Male | −5.0% | −0.0509 | −0.088 | −0.014 |
| Comorbidity score (reference group: comorbidity score=0) | ||||
| 1 | 37.7% | 0.3199 | 0.273 | 0.367 |
| >=2 | 120.5% | 0.7907 | 0.743 | 0.838 |
| Missing | 18.1% | 0.1660 | 0.106 | 0.226 |
| Region (reference group: Midwest) | ||||
| Northeast | 13.5% | 0.1265 | 0.063 | 0.190 |
| South | −2.4% | −0.0246 | −0.092 | 0.043 |
| West | 10.8% | 0.1028 | 0.046 | 0.160 |
| Neighborhood SES: education (reference group: first quartile) | ||||
| Second quartile | −9.0% | −0.0945 | −0.149 | −0.040 |
| Third quartile | −10.8% | −0.1142 | −0.184 | −0.044 |
| Fourth quartile | −18.5% | −0.2040 | −0.275 | −0.133 |
| Neighborhood SES: poverty (reference group: first quartile) | ||||
| Second quartile | −6.6% | −0.0679 | −0.119 | −0.017 |
| Third quartile | −3.8% | −0.0387 | −0.104 | 0.027 |
| Fourth quartile | −11.7% | −0.1243 | −0.193 | −0.056 |
| Stage (reference group: localized) | ||||
| Regional | −2.2% | −0.0227 | −0.076 | 0.030 |
| Distant | 29.8% | 0.2609 | 0.192 | 0.330 |
| Unstaged | 6.9% | 0.0669 | −0.039 | 0.173 |
| Grade (reference group: well differentiated) | ||||
| Moderately differentiated | −0.8% | −0.0077 | −0.068 | 0.052 |
| Poorly differentiated | 0.0% | −0.0002 | −0.070 | 0.070 |
| Undifferentiated | 2.6% | 0.0259 | −0.100 | 0.152 |
| Cell type not determined, not stated or not applicable | 4.1% | 0.0404 | −0.024 | 0.104 |
| Phase of care (reference group: initial care phase) | ||||
| Continuing care phase | −31.3% | −0.3758 | −0.412 | −0.339 |
| Terminal care phase | 48.7% | 0.3969 | 0.346 | 0.448 |
| Year of claims (reference group:2007) | ||||
| 2008 | 6.5% | 0.0628 | 0.026 | 0.100 |
| 2009 | 14.2% | 0.1331 | 0.093 | 0.173 |
| 2010 | 18.8% | 0.1724 | 0.129 | 0.216 |
| 2011 | 25.4% | 0.2262 | 0.183 | 0.269 |
| died by 2012 (reference group: alive on December 31, 2012) | ||||
| Yes | 107.2% | 0.7286 | 0.680 | 0.777 |
| Cancer drugs use (reference group: no cancer drugs) | ||||
| Conventional therapy | 57.4% | 0.4538 | 0.391 | 0.516 |
| New cancer drugs | 217.9% | 1.1566 | 1.085 | 1.228 |
| Surgery (reference group: no surgery) | ||||
| Conventional (open) surgery | 1124.7% | 2.5053 | 2.456 | 2.554 |
| New (laparoscopic) surgery | 1024.4% | 2.4199 | 2.370 | 2.470 |
| Radiotherapy (reference group: no radiotherapy) | ||||
| Conventional radiotherapy | 142.9% | 0.8874 | 0.794 | 0.980 |
| New radiotherapy | 389.3% | 1.5878 | 1.430 | 1.746 |
Note:
*:
percentage change (relative to the reference group) was calculated as 100 x [exp(estimated coefficient)-1]